Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 37.9% during trading on Friday . The company traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares traded hands during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Up 20.0 %
The firm has a market capitalization of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The stock has a 50-day moving average price of C$0.09 and a 200 day moving average price of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Using the MarketBeat Dividend Tax Calculator
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
